Biohit Oyj Press Release May 20, 2014 at 2:15 pm local time (EEST)
Biohit Oyj initiates two clinical trials for prevention of migraine-type headache attacks, testing the efficacy of Acetium® capsule in novel clinical indications. The purpose of the trial is to assess the effect of Acetium® capsule in prevention of headache attacks among patients suffering from migraine or cluster/Horton headache.
Both studies will be conducted as multi-center clinical trials in collaboration with Terveystalo Oy and Aava Medical Center altogether in six cities in Finland. Enquiries and enrollment:
Acetium® capsule in prevention of headache attacks among patients with cluster headache:
altogether, 100 subjects with clinically diagnosed cluster headache will be enrolled in the study.
Terveystalo Helsinki Kamppi
Contact: Petra Keski-Säntti, tel. 044 051 2210 (mon-fri between 4-6 pm),
petra.keski-santti@terveystalo.com
Terveystalo Tampere
Contact: Outi Salminen, tel. 030 633 4621 (mon-fri between 10 am-12 noon), outi.salminen@terveystalo.com
Terveystalo Turku
Contact: tutkimus2.turku@terveystalo.com
Terveystalo Jyväskylä
Contact: Anna Kinnunen, tel. 050 563 1802, anna.kinnunen@terveystalo.com
Terveystalo Oulu
Contact: research nurse Anu Nuojua, tel. 010 345 2931 (mon-fri between 12 noon-4 pm), anu.nuojua@terveystalo.com, research nurse Jaana Vainionpää, tel. 010 345 3151 (mon-fri between 12 noon - 4 pm.), jaana.vainionpää@terveystalo.com
Lääkärikeskus Aava Helsinki
Contact: research nurse Carita Jussila, tel. 050 591 0702 (mon-fri between 9 am -15 pm), carita.jussila@aava.fi, research nurse Anne Nyrhinen, tel. 050 591 0702 (mon-fri between 9 am -15 pm), anne.nyrhinen@aava.fi
Acetium® capsule in prevention of headache attacks among migraine patients:
a cohort of 200 patients with clinically diagnosed aural or non-aural migraine will be enrolled.
Terveystalo Helsinki Kamppi
Contact: Petra Keski-Säntti, tel. 044 051 2210 (mon-fri between 4-6 pm),
petra.keski-santti@terveystalo.com
Terveystalo Turku
Contact: tutkimus2.turku@terveystalo.com
Terveystalo Jyväskylä
Contact: Anna Kinnunen, tel. 050 563 1802, anna.kinnunen@terveystalo.com
Terveystalo Oulu
Contact: research nurse Anu Nuojua, tel. 010 345 2931 (mon-fri between 12 noon-4 pm), anu.nuojua@terveystalo.com, research nurse Jaana Vainionpää, tel. 010 345 3151 (mon-fri between 12 noon - 4 pm.), jaana.vainionpää@terveystalo.com
Lääkärikeskus Aava Helsinki
Contact: research nurse Carita Jussila, tel. 050 591 0702 (mon-fri between 9 am -15 pm), carita.jussila@aava.fi, research nurse Anne Nyrhinen, tel. 050 591 0702 (mon-fri between 9 am -15 pm), anne.nyrhinen@aava.fi
The principal investigator in both trials is docent Mikko Kallela, specialist in neurology (Helsinki University Central Hospital, Department of Neurology), and the investigator-in-charge in each center is a neurology specialist.
Study protocols:
Efficacy of Acetium® Capsule in Prevention of Headache Attacks in Migraine Patients. Randomized Intervention Trial with a Medical Device (Acetium® Capsules). (Acetium® in Migraine Prevention Study)
www.biohithealthcare.com/resource/files/research/protocol-migraine.pdf
The Efficacy of Acetium® Capsule in Prevention of Cluster Headache. Randomized Intervention Trial with a Medical Device (Acetium® Capsules). (Acetium® in Prevention of Cluster Headache Study)
www.biohithealthcare.com/resource/files/research/protocol-cluster.pdf
Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com